MusculoskeletalShenzhen Zhongge Biotechnology Co. Ltd. has disclosed interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors and/or degraders reported to be useful for the treatment of cancer, psoriasis, systemic lupus erythematosus, osteoarthritis, graft-vs.-host disease, rheumatoid arthritis, irritable bowel syndrome and chronic obstructive pulmonary disease, among others.BioWorld Science Musculoskeletal Patents
Read More…